Laura Bonanno

6.0k total citations
130 papers, 2.1k citations indexed

About

Laura Bonanno is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Laura Bonanno has authored 130 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Pulmonary and Respiratory Medicine, 63 papers in Oncology and 29 papers in Molecular Biology. Recurrent topics in Laura Bonanno's work include Lung Cancer Treatments and Mutations (57 papers), Lung Cancer Research Studies (31 papers) and Cancer Genomics and Diagnostics (23 papers). Laura Bonanno is often cited by papers focused on Lung Cancer Treatments and Mutations (57 papers), Lung Cancer Research Studies (31 papers) and Cancer Genomics and Diagnostics (23 papers). Laura Bonanno collaborates with scholars based in Italy, United States and Spain. Laura Bonanno's co-authors include Pierfranco Conté, Giulia Pasello, Valentina Guarneri, Alberto Pavan, Ilaria Attili, Adolfo Favaretto, Stefano Indraccolo, Deborah Garbee, Alessandro Dal Maso and John T. Paige and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Laura Bonanno

124 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura Bonanno Italy	23	1.0k	891	643	566	185	130	2.1k
Som D. Mukherjee Canada	25	968 1.0×	499 0.6×	560 0.9×	414 0.7×	103 0.6×	85	2.0k
Athanasios Pallis Greece	31	1.5k 1.5×	1.1k 1.2×	401 0.6×	369 0.7×	341 1.8×	103	2.7k
David M. Cognetti United States	25	932 0.9×	672 0.8×	644 1.0×	517 0.9×	128 0.7×	167	2.7k
Desmond Yip Australia	30	1.6k 1.6×	938 1.1×	579 0.9×	398 0.7×	262 1.4×	162	2.9k
Wu‐Wei Lai Taiwan	29	619 0.6×	744 0.8×	935 1.5×	498 0.9×	231 1.2×	115	2.5k
Norbert Marschner Germany	25	1.3k 1.3×	649 0.7×	407 0.6×	349 0.6×	124 0.7×	153	2.2k
Takefumi Satoh Japan	33	665 0.7×	1.6k 1.8×	878 1.4×	441 0.8×	126 0.7×	157	3.6k
Hope E. Uronis United States	24	1.5k 1.5×	848 1.0×	428 0.7×	478 0.8×	300 1.6×	119	2.3k
Colin Hessel United States	14	596 0.6×	595 0.7×	420 0.7×	262 0.5×	711 3.8×	25	2.1k
Sadhana Kannan India	24	512 0.5×	780 0.9×	694 1.1×	384 0.7×	221 1.2×	145	2.6k

Countries citing papers authored by Laura Bonanno

Since Specialization

Citations

This map shows the geographic impact of Laura Bonanno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Bonanno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Bonanno more than expected).

Fields of papers citing papers by Laura Bonanno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Bonanno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Bonanno. The network helps show where Laura Bonanno may publish in the future.

Co-authorship network of co-authors of Laura Bonanno

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Bonanno. A scholar is included among the top collaborators of Laura Bonanno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Bonanno. Laura Bonanno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ferro, Alessandra, et al.. (2024). The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies. Critical Reviews in Oncology/Hematology. 196. 104295–104295. 29 indexed citations

John, Thomas, Christian Grohé, Jonathan W. Goldman, et al.. (2024). Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8005–8005. 15 indexed citations

Pasello, Giulia, Alessandro Del Conte, Fabiana Letizia Cecere, et al.. (2024). Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World. The Oncologist. 29(7). 596–608. 2 indexed citations

Cascone, Tina, Laura Bonanno, M. A. Lieberman, et al.. (2024). PL02.07 Neocoast-2: Efficacy and Safety of Neoadjuvant Durvalumab (D) + Novel Anticancer Agents + CT and Adjuvant D ± Novel Agents in Resectable NSCLC. Journal of Thoracic Oncology. 19(10). S1–S2. 6 indexed citations

Bianco, Paola Del, Elisabetta Zulato, Ilaria Attili, et al.. (2024). Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer. npj Precision Oncology. 8(1). 234–234. 6 indexed citations

Cousin, Sophie, Luis Paz‐Ares, Andrea Fülöp, et al.. (2023). Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.. Journal of Clinical Oncology. 41(16_suppl). 8591–8591. 1 indexed citations

Pasello, Giulia, Giorgio Pigato, Loredana Urso, et al.. (2023). 2021P Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study. Annals of Oncology. 34. S1074–S1074. 1 indexed citations

Pasello, Giulia, Loredana Urso, Ilaria Cavallari, et al.. (2023). 2020P Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study. Annals of Oncology. 34. S1073–S1074. 1 indexed citations

Ferro, Alessandra, Matteo Sepulcri, Marco Schiavon, et al.. (2022). The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments. Cancers. 14(22). 5700–5700. 13 indexed citations

10.

Zulato, Elisabetta, Valeria Tosello, Giorgia Nardo, et al.. (2021). Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) Patients. Diagnostics. 11(8). 1468–1468. 10 indexed citations

11.

Maso, Alessandro Dal, Alessandra Ferro, Sara Pilotto, et al.. (2021). Real-World Data on Treatment Outcomes in EGFR -Mutant Non-Small-Cell Lung Cancer Patients Receiving Osimertinib in Second or Further Lines. Future Oncology. 17(19). 2513–2527. 8 indexed citations

12.

Attili, Ilaria, Laura Bonanno, Niki Karachaliou, et al.. (2020). SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. Translational Lung Cancer Research. 9(5). 1810–1821. 11 indexed citations

13.

Lohinai, Zoltán, Laura Bonanno, Alberto Pavan, et al.. (2019). Neutrophil–lymphocyte ratio is prognostic in early stage resected small-cell lung cancer. PeerJ. 7. e7232–e7232. 27 indexed citations

14.

Maso, Alessandro Dal, Elisa Roca, Sara Pilotto, et al.. (2019). Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clinical Lung Cancer. 21(1). 1–14.e3. 19 indexed citations

15.

Maso, Alessandro Dal, et al.. (2019). Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?. Critical Reviews in Oncology/Hematology. 138. 87–103. 17 indexed citations

16.

Attili, Ilaria, Niki Karachaliou, Pierfranco Conté, Laura Bonanno, & Rafael Rosell. (2018). Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. Expert Review of Anticancer Therapy. 18(10). 1021–1030. 24 indexed citations

17.

Bonanno, Laura, Angela De Paoli, Elisabetta Zulato, et al.. (2017). LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non–Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. Clinical Cancer Research. 23(13). 3316–3324. 39 indexed citations

18.

Bonanno, Laura, et al.. (2015). Effectiveness of ondansetron as an adjunct to lidocaine intravenous regional anesthesia on tourniquet pain and postoperative pain in patients undergoing elective hand surgery: a systematic review protocol. The JBI Database of Systematic Reviews and Implementation Reports. 13(1). 27–38. 8 indexed citations

19.

Molina‐Vila, Miguel Ángel, Jordi Bertrán-Alamillo, Amaya Gascó, et al.. (2014). Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 20(17). 4647–4659. 125 indexed citations

20.

Bonanno, Laura, et al.. (2011). Evidence-Based Strategies to Prevent Postoperative Respiratory Dysfunction for Patients with Obstructive Sleep Apnea Undergoing Laparoscopic Bariatric Surgery. Bariatric Nursing and Surgical Patient Care. 6(2). 79–84. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact